Dosing and uses of Teveten HCT, Teveten Plus (eprosartan-hydrochlorothiazide)
Adult dosage forms and strengths
eprosartan/hydrochlorothiazide
tablet
- 600mg/12.5mg
- 600mg/25mg
Hypertension
600 mg/12.5 mg to 600 mg/25 mg PO qDay
Pediatric dosage forms and strengths
Safety and efficacy not established
Teveten HCT, Teveten Plus (eprosartan-hydrochlorothiazide) adverse (side) effects
1-10%
Eprosartan
- Upper respiratory infection (8%)
- Cough (4%)
- Abdominal pain (2%)
- Fatigue (2%)
Hydrochlorothiazide
- Hypotension
- Anorexia
- Epigastric distress
- Hypokalemia
- Phototoxicity
Warnings
Black box warnings
Discontinue as soon as possible when pregnancy is detected; affects renin-angiotensin system causing oligohydramnios, which may result in fetal injury and/or death
Contraindications
Hypersensitivity to eprosartan, hydrochlorothiazide, or sulfonamides
Pregnancy (2nd/3rd trimesters): Significant risk of fetal/neonatal morbidity and mortality
Anuria
Do not coadminister with aliskiren in patients with diabetes
Cautions
Acute transient myopia and acute angle-closure glaucoma has been reported, particularly with history of sulfonamide or penicillin allergy (hydrochlorothiazide is a sulfonamide)
Not for initial treatment
Dual blockade of the renin angiotensin system with ARBs, ACE inhibitors, or aliskiren associated with increased risk for hypotension, hyperkalemia, and renal function changes (including acute renal failure) compared to monotherapy
Pregnancy and lactation
Pregnancy category: C (1st trimester); D (2nd & 3rd trimesters)
Lactation: excretion in milk unknown/not recommended
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
